American Association for Cancer Research Annual Meeting

The latest news from AACR, including researcher interviews and physician perspective.

Meeting News CoveragePerspective

Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma

April 20, 2015
PHILADELPHIA — Patients with treatment-naive advanced melanoma who underwent simultaneous treatment with ipilimumab and nivolumab demonstrated…
Meeting News Coverage

ACS, Stand Up To Cancer announce lung cancer research initiative

April 20, 2015
PHILADELPHIA — Stand Up to Cancer, or SU2C, and the American Cancer Society today announced the formation of a $20 million lung cancer…
Meeting News CoveragePerspective

T-cell immunotherapy appears effective in post-HSCT lymphoproliferative disorder

April 20, 2015
PHILADELPHIA — A new type of T cell-based immunotherapy induced response in a majority of patients with Epstein-Barr virus-associated…
Meeting News CoveragePerspective

First-line pembrolizumab superior to ipilimumab for advanced melanoma

April 19, 2015
PHILADELPHIA — Patients with advanced melanoma who received first-line pembrolizumab achieved significantly prolonged OS and PFS compared with…
Meeting News CoveragePerspective

PD-L1 expression linked to pembrolizumab activity in advanced NSCLC

April 19, 2015
PHILADELPHIA — Pembrolizumab yielded durable response rates and demonstrated tolerability in previously treated and treatment-naive patients…
Meeting News CoveragePerspectivePublication Exclusive

FGFR-targeted therapy demonstrated activity in solid tumors

HemOnc Today, May 25, 2014
Patients with solid tumors with fibroblast growth receptor genetic alterations demonstrated tumor shrinkage with the novel agent BGJ398, according to…
Meeting News CoveragePerspective

FGFR-targeted therapy demonstrated activity in solid tumors

April 9, 2014
Patients with solid tumors with fibroblast growth receptor genetic alterations demonstrated tumor shrinkage with the novel agent BGJ398, according to…
Meeting News CoveragePerspective

Researchers identify breast cancer subtype that may benefit from neratinib

April 8, 2014
The combination of chemotherapy plus neratinib induced a higher rate of complete response in patients with HER-2–positive, HR-negative breast…
Meeting News CoveragePerspective

Novel small molecule inhibitor shows promise in hematologic malignancies

April 7, 2014
The novel human bromodomain protein inhibitor OTX015 demonstrated clinical activity among patients with various hematologic malignancies, according…
Meeting News Coverage

PD-L1 expression predicted response to immunotherapy in melanoma

April 7, 2014
Patients with advanced melanoma whose tumors expressed programmed death ligand-1 demonstrated improved immune responses and longer PFS after…